3 Discussion
ECMO is commonly used in pediatric patients with CHD, particularly in the setting of low-output failure, arrhythmia, cardiopulmonary arrest, or inability to transition from CPB [5].However, despite significant advances in ECMO techniques and management over the last several years, prognosis remains poor[6]. The underlying causes of death vary from cardiovascular events to organ failure, including GI, renal, neurologic, coagulation, and it carries a significant cost burden[7]. Neonates are special population, who’s cardiomyocytes are softer with less contractile tissue and lower energy reserves. Longer CPB time leads to poor myocardial cell compliance and insensitivity to drugs, and these lead to heart failure controlled by drugs difficultly after open-heart surgery. According to the latest statistics from ELSO 2017, the neonatal survival rate of CHD is 47% and discharge rate is 39% [8]. In our study, although the survival rate of neonate is as high as 52.17%, there are many risk factors that affect the outcomes.